KRYS

Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock

Retrieved on: 
Wednesday, December 1, 2021
William Blair & Company, Public expenditure, Security (finance), Sale, Netherton, Company, Exercise, Form, Netherton syndrome, Broadridge Financial Solutions, SEC, SEC filing, 3rd Floor, U.S. Securities and Exchange Commission, Telephone, KRYS, Prospectus, Research, Investment, Attention, GLOBE, BofA Securities, LLC, Cystic fibrosis, NASDAQ, Degenerative disease, Pharmaceutical industry

The Company and certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 400,000 shares of the Companys common stock offered in the public offering.

Key Points: 
  • The Company and certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 400,000 shares of the Companys common stock offered in the public offering.
  • The gross proceeds to the Company from this offering are expected to be approximately $200 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company.
  • The offering is expected to close on or about December 3, 2021, subject to satisfaction of customary closing conditions.
  • Goldman Sachs & Co. LLC, BofA Securities, Cowen and William Blair are acting as the book-running managers for the offering.

Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock

Retrieved on: 
Monday, November 29, 2021
William Blair & Company, Public expenditure, Security (finance), Sale, Netherton, Company, Exercise, Form, Netherton syndrome, Broadridge Financial Solutions, SEC, 3rd Floor, SEC filing, U.S. Securities and Exchange Commission, Telephone, KRYS, Prospectus, Research, Investment, Attention, GLOBE, BofA Securities, LLC, Cystic fibrosis, NASDAQ, Degenerative disease, Pharmaceutical industry

PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the Company), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering of its common stock.

Key Points: 
  • PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the Company), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering of its common stock.
  • The Company and certain selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional $30 million of the shares of the Companys common stock offered in the public offering.
  • Goldman Sachs & Co. LLC, BofA Securities, Cowen and William Blair are acting as the book-running managers for the offering.
  • A preliminary prospectus supplement and accompanying base prospectus relating to the offering and the shares of common stock being offered will be filed with the SEC.

Thinking about trading options or stock in Pfizer, American Airlines, Krystal Biotech, NVIDIA, or Alibaba?

Retrieved on: 
Monday, November 29, 2021
PFE, Wall Street, NVDA, AAL, KRYS, BABA, Retail

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, AAL, KRYS, NVDA, and BABA.

Key Points: 
  • NEW YORK, Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, AAL, KRYS, NVDA, and BABA.
  • Click a link below then choose between in-depth options trade idea report or a stock score report.
  • Options Report Ideal trade ideas on up to seven different options trading strategies.
  • The report shows all vital aspects of each option trade idea for each stock.

Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa

Retrieved on: 
Monday, November 29, 2021
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Company, The, Lists of diseases, Krystal, Physician, EST, Squamous cell carcinoma, Conference call, Risk, GLOBE, Marketing, COL7, Biologics license application, Associate, LinkedIn, Blister, Degenerative disease, Food, CGMP, Private Securities Litigation Reform Act, OLE, COL7A1, CEO, Epidermolysis bullosa, ID, Investor, Tears, Food and Drug Administration, Research, Wound, Trauma, EB, Suma, Finger, VAS, Caregiver, VII, Conference, Epidermis, Clinical trial, DEB, U.S. Securities and Exchange Commission, Skin, Twitter, NASDAQ, Priority, Wound healing, ASTRA, FDA, Patient, Tissue, Safety, Pivotal, Open-label trial, MAA, Stanford University, BLA, Dermis, KRYS, EMA, Webcast, Fibrosis, Disease, Medical imaging, Pharmaceutical industry, Birth control

PITTSBURGH, Nov. 29, 2021 (GLOBE NEWSWIRE) --  Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced positive topline results from the pivotal GEM-3 trial of investigational beremagene geperpavec (B-VEC), now known as VYJUVEKTM, for the treatment of dystrophic Epidermolysis Bullosa (dystrophic EB).

Key Points: 
  • Todays positive B-VEC results represent the culmination of years of study on the molecular basis and genetic correction of this disease.
  • Finally, dystrophic EB patients may have an easily administered genetically targeted therapy which has been shown to promote durable wound healing in this clinical trial.
  • We founded Krystal less than six years ago with the goal of developing a non-invasive, genetically corrective therapy for dystrophic EB.
  • ET, to discuss topline results from the pivotal GEM-3 trial and the VYJUVEKTM program.

Jeune Aesthetics to Present Pre-clinical Data Highlighting the Potential of KB303 in Elastin Production at the ASDS 2021 Virtual Meeting

Retrieved on: 
Friday, November 19, 2021
Tissue, Jeune, Skin, ASDS, Ageing, Cell, Private Securities Litigation Reform Act, Biology, Krystal, Dermis, KRYS, Atrophy, U.S. Securities and Exchange Commission, Elastin, ELN, Twitter, Extracellular matrix, GLOBE, NASDAQ, Marketing, Elasticity, Society, LinkedIn, Vaccine, Pharmaceutical industry

The data will be presented at the American Society for Dermatologic Surgery (ASDS) 2021 Virtual Meeting to be held November 19-21, 2021.

Key Points: 
  • The data will be presented at the American Society for Dermatologic Surgery (ASDS) 2021 Virtual Meeting to be held November 19-21, 2021.
  • Using our proprietary gene delivery platform, weve engineered KB303 to deliver the ELN gene and help cells naturally replenish elastin that has been lost due to photo-damage and aging.
  • Were excited to present these first-ever data on KB303 that, while early, show promise in the potential to be the first approach to produce elastin to naturally improve skin elasticity.
  • These forward-looking statements should not be relied upon as representing Krystals views as of any date subsequent to the date of this release.

Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress

Retrieved on: 
Monday, November 8, 2021
Good laboratory practice, Society, OLE, Private Securities Litigation Reform Act, III, Krystal, Clinical trial, General manager, U.S. Securities and Exchange Commission, NASDAQ, Jeune, CEO, Blood, Investment, Degenerative disease, Elasticity, ASTRA, Financial result, Elastin, Cystic fibrosis, Program, COL3A1, File, Epidermolysis bullosa, Twitter, Conference, NCT, Company, Research, GLOBE, LinkedIn, Diagnosis, Galderma, CF, DEB, KRYS, Patient, Poster, Skin, Marketing, IND, Cryptocurrency, Medical device, Pharmaceutical industry, Animal

PITTSBURGH, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today reported financial results and key operational progress updates for the third quarter ending September 30, 2021.

Key Points: 
  • Strong balance sheet with September 30, 2021 cash, cash equivalents, and investments of $362.3 million
    PITTSBURGH, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (Krystal) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today reported financial results and key operational progress updates for the third quarter ending September 30, 2021.
  • Financial results for the quarter ended September 30, 2021:
    Cash, cash equivalents, and investments totaled $362.3 million on September 30, 2021, compared to $271.3 million as of December 31, 2020.
  • For additional information on the Companys financial results for the third quarter ended September 30, 2021, refer to form 10-Q filed with the U.S. Securities and Exchange Commission.
  • However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Frazier Healthcare Partners Announces Several Promotions on Life Sciences Team

Retrieved on: 
Thursday, October 28, 2021
Biotechnology, Finance, Health, Professional Services, Pharmaceutical, Frazier Healthcare Partners, Sanofi Pasteur, Science, RNA transfection, ISEE, Biology, FLAC, Life, Eli Lilly, Initial public offering, O'Hara, U.S. Treasury, Treasury, General partnership, TRIL, Mergers and acquisitions, Public relations, NASDAQ, Machine learning, Capital market, List of life sciences, Equity capital markets, Roche, KRYS, Amgen, Senior advisor, General Atlantic, Morgan Stanley, Flagship Pioneering, Mergers & Acquisitions, Marketing, Investment, J. P. Morgan, Cancer, Growth, Safety, Acquisition, Intellectual property, Sanofi–Translate Bio COVID-19 vaccine, Biophysics, Fine chemical, Financial services

Dr. Brush joined the Frazier Life Sciences team in 2016 and co-leads Fraziers public equity investment strategy.

Key Points: 
  • Dr. Brush joined the Frazier Life Sciences team in 2016 and co-leads Fraziers public equity investment strategy.
  • Mr. Topper originally joined the Frazier Life Sciences team as a Senior Advisor in 2020 and currently serves as Chief Financial Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ: FLAC).
  • Mr. Cabral joined the Frazier Life Sciences team in 2021 and focuses on identifying, evaluating, and creating new ventures.
  • It is very gratifying to see our team expand its capabilities, stated Patrick Heron, Managing Partner on Fraziers Life Sciences team.

Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa

Retrieved on: 
Tuesday, October 26, 2021
Safety, COL7, Suma, Blister, EMA, Patient, NASDAQ, Concha bullosa, FDA, KRYS, VII, Degenerative disease, Skin, GLOBE, DEB, Pharmaceutical industry

The GEM-3 trial is a randomized, double-blind, intra-patient placebo-controlled study designed to evaluate the efficacy and safety of B-VEC for the treatment of DEB.

Key Points: 
  • The GEM-3 trial is a randomized, double-blind, intra-patient placebo-controlled study designed to evaluate the efficacy and safety of B-VEC for the treatment of DEB.
  • The trial enrolled 31 patients ranging in ages from one (1) year to forty-four (44) years old.
  • Less than ten percent (10%) of enrolled patients have the dominant form of dystrophic epidermolysis bullosa (DDEB).
  • However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis

Retrieved on: 
Tuesday, October 19, 2021
Krystal, Clinical trial, IND, Cystic fibrosis, NASDAQ, Poster, Death, COVID-19, CFTR, Private Securities Litigation Reform Act, Lung, Degenerative disease, Disease, Pharmacology, Research, KRYS, Trinidad and Tobago Securities and Exchange Commission, GLOBE, Patient, CF, Conference, Pancreas, Toxicology, GLP, Trial of the century, Marketing, Epithelium, U.S. Securities and Exchange Commission, Pharmaceutical industry, Antibiotics

The data include more detailed results from the IND-enabling good laboratory practice (GLP) toxicology study of KB407 from which top line results were previously announced .

Key Points: 
  • The data include more detailed results from the IND-enabling good laboratory practice (GLP) toxicology study of KB407 from which top line results were previously announced .
  • Cystic fibrosis is the most common fatal inherited disease in the United States, affecting more than 80,000 patients worldwide.
  • Lack of functional CFTR in secretory airway epithelial cells causes dehydrated mucus buildup in the lungs, pancreas and other organs.
  • According to the US Cystic Fibrosis Foundation (CFF), the median age at death for patients with CF in the United States was 30.8 years in 2018.

Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT

Retrieved on: 
Thursday, October 14, 2021
Pharmacology, Plasma, Gene, European Society of Gene and Cell Therapy, Blood, AATD, Private Securities Litigation Reform Act, Liver, Congress, KRYS, Degenerative disease, Treatment, Therapy, ESGCT, Marketing, Krystal, Liver disease, Patient, SERPINA1, Cell, AAT, GLOBE, Trinidad and Tobago Securities and Exchange Commission, 2021 Essex County Council election, Failure rate, NASDAQ, Research, Genetic disorder, COVID-19, U.S. Securities and Exchange Commission, Pharmaceutical industry, Medical device

KB408 is an inhaled, redosable gene therapy designed to increase production of normal, fully functional AAT protein directly in the lung tissue to correct the deficiency.

Key Points: 
  • KB408 is an inhaled, redosable gene therapy designed to increase production of normal, fully functional AAT protein directly in the lung tissue to correct the deficiency.
  • e-Poster Title: Preclinical Pharmacology of KB408, an HSV-1-based Gene Therapy Vector, for the Treatment of Alpha-1 Antitrypsin Deficiency
    Full text of accepted abstracts will be made available to registrants on October 19, 2021, at 8:00am CEST.
  • AATD is caused by mutations in the SERPINA1 gene that lead to decreased levels and/or decreased functionality of AAT.
  • However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.